Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Dose-escalation and Expansion Trial With the Antibody-drug Conjugate BYON3521 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With c-MET Expressing Locally Advanced or Metastatic Solid Tumours

NCT05323045 is registered in ClinicalTrials.gov with Byondis B.V. as lead sponsor.

NCT NCT05323045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05323045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Dose-escalation and Expansion Trial With the Antibody-drug Conjugate BYON3521 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With c-MET Expressing Locally Advanced or Metastatic Solid Tumours
Lead sponsor
Byondis B.V.
Phase
Phase 1
Overall status
Completed
Start date
March 21, 2022
Completion date
September 25, 2024
Enrollment
31 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor